Antibacterial Therapy by Pathogen Osmolality Disruption

Information

  • Research Project
  • 6739580
  • ApplicationId
    6739580
  • Core Project Number
    R43AI058410
  • Full Project Number
    1R43AI058410-01
  • Serial Number
    58410
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/15/2004 - 21 years ago
  • Project End Date
    3/31/2005 - 21 years ago
  • Program Officer Name
    KORPELA, JUKKA K.
  • Budget Start Date
    4/15/2004 - 21 years ago
  • Budget End Date
    3/31/2005 - 21 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/2/2004 - 22 years ago

Antibacterial Therapy by Pathogen Osmolality Disruption

DESCRIPTION (provided by applicant): The recent threat of bioterrorism has intensified the need for new classes of antibiotics. Among biodefense category A bacterial pathogens, many species are currently susceptible to existing antibiotics. However, the development of bioweapon strains of Bacillus anthracis and Yersinia pestis that are resistant to multiple antibiotics is a distinct possibility. In addition to agents present on the biodefense pathogen list, other forms of bacterial infections continue to be a common cause of morbidity and mortality. To begin addressing these unmet needs, we are proposing a focused study targeting bacterial mechanosensitive (MS) channels. MS channels enable bacteria to rapidly adapt to osmotic changes in their environment. Although non-essential, gain-of-function (GOF) mutations that constitutively activate MS channels are bactericidal. Over the initial phase of this project, we will demonstrate the "drugability" of the E. coil MS channel using our proprietary Mpex minicell technology. The Mpex minicell will enable high-throughput, small molecule and natural product screening to identify compound activators that mimic the lethal GOF phenotype. In conjunction with these studies, we will validate the function of homologous, biodefense-related MS channels from B. anthracis and Y. pestis. Using E. coil and Mpex minicells, we will also characterize the GOF modulators identified against the E. coil MS target for activity against these pathogenic MS channeling proteins. Thus, Phase I stands as a proof-of-concept for the use of the MS target and Mpex minicells together to effectively identify novel antibacterial leads, and provides in parallel further functional target validation of MS homologs found in various biodefense category A pathogenic species. Following successful validation in Phase I, Phase II studies will include screening of these pathogenic MS homologs using Mpex minicells, prioritization of hits, and lead optimization to produce an IND-enabling candidate molecule.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    265985
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:265985\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MPEX PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
    159990550
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921095754
  • Organization District
    UNITED STATES